ArticlePulmonary therapy2025
A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID).
Article in Pulmonary therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06291831 (A Retrospective Observational Non-Interventional Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HRU) Among COVID-19 Patients With or Without Nirmatrelvir/Ritonavir (PAXLOVID™) Treatment in the Kingdom of Bahrain.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionThis study was undertaken in COVID-19 patients treated with and without Paxlovid™ (Paxlovid) in an outpatient setting to determine hospitalization from the community.
methodsThis retrospective secondary data observational cohort study was conducted between February and November 2022. All patients diagnosed by polymerase chain reaction for COVID-19 and at risk of COVID-19 disease progression were offered Paxlovid in the outpatient setting. Potential associations between Paxlovid use and likelihood of hospitalization, antibiotic use, and other clinical outcomes were explored using regression models as appropriate (i.e., logistic, multinomial, ordinal), adjusted for World Health Organization risk classification.
resultsOf 3011 COVID-19 patients offered Paxlovid, 2005 (67%) were treated with Paxlovid and 1006 (33%) chose not to take treatment. There was no evidence of a difference between groups in terms of vaccination status, viral load, age, or gender, although more patients of Arab ethnicity chose not to take treatment (p < 0.001). There were fewer hospital admissions in the group that took Paxlovid (p < 0.001). Some evidence of a reduction in the number of hospitalizations was found when adjusted for World Health Organization risk category (adjusted odds ratio [aOR] 0.60, 95% confidence interval [CI] 0.45-0.77), and a reduction was similarly found for the number of hospitalizations among patients with readmission (aOR 0.47, 95% CI 0.26-0.84). A reduction in the odds of antibiotic use was observed in the treated group for any cause (aOR 0.80, 95% CI 0.67-0.94) and specifically for COVID-19 (aOR 0.58, 95% CI 0.44-0.77).
conclusionsPaxlovid treatment reduced hospitalization and antibiotic use, indicating its benefit in reducing severe outcomes and healthcare burden and supporting its use for reducing severe outcomes in COVID-19 patients.
trial registrationClinicalTrials.gov identifier, NCT06291831.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.